Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Sep 8, 2003
Regulation
PDE-4 inhibitors
...GlaxoSmithKline Ariflo COPD Under review for COPD Altana Roflumilast Asthma, COPD Ph III Pfizer Otsuka
OPC-6535
...
Read More
BioCentury
|
Jul 28, 2003
Clinical News
OPC-6535: Phase III
...trials will enroll 750 patients in total. Otsuka Pharmaceutical Co. Ltd. , Tokyo, Japan Product:
OPC-6535
...
Read More
BioCentury
|
Jul 22, 2003
Clinical News
Otsuka starts ulcerative colitis Phase III
...Otsuka (Tokyo, Japan) began two Phase III trials of its
OPC-6535
, a phosphodiesterase 4 (PDE...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page